Natixis Advisors LLC grew its stake in Stevanato Group S.p.A. (NYSE:STVN – Free Report) by 20.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 51,343 shares of the company’s stock after purchasing an additional 8,669 shares during the period. Natixis Advisors LLC’s holdings in Stevanato Group were worth $1,027,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Royce & Associates LP boosted its position in Stevanato Group by 45.8% in the third quarter. Royce & Associates LP now owns 343,159 shares of the company’s stock valued at $6,863,000 after buying an additional 107,869 shares in the last quarter. King Wealth Management Group boosted its holdings in shares of Stevanato Group by 30.2% during the 3rd quarter. King Wealth Management Group now owns 94,800 shares of the company’s stock valued at $1,896,000 after acquiring an additional 22,000 shares in the last quarter. Sivik Global Healthcare LLC bought a new stake in Stevanato Group during the 3rd quarter worth $2,800,000. Zions Bancorporation N.A. bought a new position in Stevanato Group in the third quarter valued at about $1,049,000. Finally, Pembroke Management LTD boosted its stake in shares of Stevanato Group by 143.7% during the third quarter. Pembroke Management LTD now owns 1,051,140 shares of the company’s stock valued at $21,023,000 after purchasing an additional 619,747 shares in the last quarter.
Wall Street Analyst Weigh In
Separately, Citigroup lowered their price objective on Stevanato Group from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday, August 7th.
Stevanato Group Stock Performance
Shares of Stevanato Group stock opened at €20.04 ($21.09) on Wednesday. Stevanato Group S.p.A. has a twelve month low of €16.56 ($17.43) and a twelve month high of €34.73 ($36.56). The company’s fifty day moving average is €19.45 and its 200 day moving average is €19.64. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21.
Stevanato Group (NYSE:STVN – Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported €0.12 ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.13 ($0.14) by (€0.01) (($0.01)). The company had revenue of €277.90 million for the quarter, compared to the consensus estimate of €274.36 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Stevanato Group’s revenue was up 2.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.16 earnings per share. On average, sell-side analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Featured Stories
- Five stocks we like better than Stevanato Group
- Top Biotech Stocks: Exploring Innovation Opportunities
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- How to Buy Cheap Stocks Step by Step
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- Stock Average Calculator
- Why Amazon Shares May Never Trade Below $200 Again
Want to see what other hedge funds are holding STVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stevanato Group S.p.A. (NYSE:STVN – Free Report).
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.